



The ACME Laboratories Ltd.
MANUFACTURERS OF ETHICAL DRUGS & MEDICINES

ISO 9001: 2015 CERTIFIED COMPANY

Ref. No. ACME/CA/CS/0010/2018

15 January 2018

The Chairman

Bangladesh Securities and Exchange Commission
Securities Commission Bhaban
E-6/C, Agargaon,
Sher-e-Bangla Nagar Administrative Area,
Dhaka-1207

Subject: Audited Status Report on utilization of Initial Public Offering proceeds of The ACME Laboratories Ltd.

Dear Sir,

In compliance with the clause 3 & 4 of Part-C of the Letter of Consent vide no. BSEC/CI/BB-03/2014/143; dated: 15 March 2016 accorded by your esteemed organization, we are pleased to enclose herewith the Audited Status Report (as per revised format) on utilization of Initial Public Offering proceeds of The ACME Laboratories Ltd. duly authenticated by the Board of Directors in its 82nd Meeting held on 15 January 2018 for your kind perusal and record please.

Thanking you and assuring our best attention for all the time to come.

Mizanur Rahman Sinha
Managing Director



Enclosed: As stated above

Copy to:

01. The Managing Director, Dhaka Stock Exchange Limited
02. The Managing Director, Chittagong Stock Exchange Limited
03. The Chief Executive Officer, ICB Capital Management Limited

Corporate Office:
Court de la ACME

1/4 Kallayanpur, Mirpur Road
Dhaka-1207, Bangladesh.
Phone : +88-02-9004194-6
Fax : +88-02-9016872
E-mail : headoffice@acmeglobal.com

www.acmeglobal.com

Plant:

Dhamrai, Dhaka, Bangladesh.
Phone : +88-02-7730881-2
+88-02-7730816-7, 7730142
Fax : +88-02-7730141
E-mail : plant@acmeglobal.com

Auditors' Report



Name of Client

The ACME Laboratories Ltd.
Utilization of IPO Proceeds
for the month ended 31 December 2017

পিনাকী এণ্ড কোম্পানী
Pinaki & Company

AHSANDELL, 2/A, Mymensingh Road (2nd Floor), Shahbag, Dhaka-1000, Bangladesh

Tel # 966-0944, 966-5095, Fax # 88-02-9672726

E-mail : pinaki_co@yahoo.com



AUDITORS' REPORT
on
Utilization of IPO Proceeds

We have audited the annexed Statement of Initial Public Offering (IPO) Proceeds Utilization of **The ACME Laboratories Ltd.** for the month ended 31 December 2017.

Management's Responsibility for the IPO proceeds Utilization

Management is responsible for the preparation and fair presentation of these IPO proceeds utilization statement in accordance with Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

Auditor's Responsibility

Our responsibility is to express an independent opinion on these Initial Public Offering (IPO) proceeds utilization statement based on our audit. We conducted our audit in accordance with Bangladesh Standards on Auditing (BSA), Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our Opinion, the Statement of Initial Public Offering (IPO) Proceeds Utilization, Prepared in accordance with Bangladesh Securities and Exchange Commission Rules 1987 and Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 gives a true and fair view of the statement for the month ended 31 December 2017 and comply with the resolution of 40th AGM of the company.

As per TOR, We draw attention to the following matter:

1. The Company has utilized cumulative amounting Tk.710,379,591 up to 31 December 2017 out of which amounting Tk. 158,605,050 is utilized during the month of December 2017 in respect of Steroid and Hormone Project.



2. The Company has utilized cumulative amounting Tk.160,165,395 up to 31 December 2017 out of which amounting Tk. 10,054,049 is utilized during the month of December 2017 in respect of Penicillin Project.
3. The Company has also utilized cumulative amounting Tk.102,818,652 up to 31 December 2017 in respect of Active Pharmaceuticals Ingredients (API) Project.

We also state that:

- a) IPO proceeds have been utilized for the purposes as specified in the resolution of 40th AGM of the company;
- b) IPO proceeds have been utilized in line with the conditions of the BSEC's consent letter for the IPO;
- c) Utilization of IPO proceeds is being under completion within the time frame as specified in the resolution of 40th AGM of the company;
- d) Utilization of IPO proceeds is accurate for the purpose of the company as mentioned in the resolution of 40th AGM of the company;
- e) Audit statement has been made on verification of all necessary documents/papers/vouchers in support of utilization of IPO proceeds making reconciliation with bank statements.

Date :15 January, 2018
Dhaka.

Pinaki & Co.

Pinaki & Company
Chartered Accountants



Report on Utilization of IPO Proceeds
For the Month of December 2017

Name of the Company:

Amount (BDT) of capital raised through IPO:

Date of Close of Subscription:

Proceeds Receiving Date:

Last Date of Full Utilization of IPO Fund as per prospectus/40th AGM

The ACME Laboratories Ltd.

BDT 4,096,000,000 (Received amount BDT 4,095,015,603.38 net of foreign currency conversion loss)

21 April 2016

11 April 2016 to 21 April 2016

As stated in time line as per prospectus and revised time line columns

S.L	Purpose mentioned in the Prospectus/40th AGM	Time line as per Prospectus	Revised Time line	Cost Breakdown	Amount as per Prospectus	Amount as per revised utilization Plan	Opening	During the Month	Status of Utilization			Total un utilized amount	Un utilized %	Remarks
									Total Utilized Amount	Utilized %	Utilized %			
1	Steroid and Hormone Project	Within 2 years of receiving IPO fund, i.e., 2018	N/A	Civil Construction Machinery & Equipment Utility Warehouse Vehicle Consultancy fee Contingencies Sub Total	335,800,000 598,600,000 339,600,000 39,500,000 5,000,000 26,300,000 13,200,000 1,358,000,000	335,800,000 598,600,000 339,600,000 39,500,000 5,000,000 26,300,000 13,200,000 1,358,000,000	298,193,244 13,809,520 234,299,876 1,146,901 3,125,000 1,200,000 -	7,559,286 149,545,764 1,500,000 -	305,752,530 163,355,284 233,799,876 1,146,901 3,125,000 1,200,000 -	91.05% 27.29% 69.43% 2.90% 62.50% 4.56% 0.00%	91.05% 27.29% 69.43% 2.90% 62.50% 4.56% 0.00%	30,047,470 435,244,716 103,800,124 38,353,099 1,875,000 25,100,000 13,200,000 647,620,409	8.95% 72.71% 30.57% 97.10% 37.50% 95.44% 100.00% 47.69%	
2	Oncology project converted into Penicillin Project (Revised)	Within 2.5 years of receiving IPO fund	Within the month of March 2018	Civil Construction Machinery & Equipment Utility Warehouse Vehicle Consultancy fee Contingencies Sub Total	335,800,000 367,000,000 350,000,000 50,000,000 5,000,000 22,100,000 11,100,000 1,141,000,000	335,800,000 367,000,000 350,000,000 50,000,000 5,000,000 22,100,000 11,100,000 1,141,000,000	76,910,295 764,848 70,959,591 56,362 -	10,054,049 -	86,964,344 764,848 70,959,591 56,362 -	74.97% 0.58% 60.57% 0.27% 0.00%	74.97% 0.58% 60.57% 0.27% 0.00%	29,035,656 131,534,672 46,194,409 20,526,338 3,000,000 4,543,530 5,000,000 239,834,605	25.03% 99.42% 39.43% 99.73% 100.00% 76.19% 100.00% 59.96%	Utilization Plan has been approved in 40th AGM as on 7 November 2016 and IPO Utilization Proceeds certified by M/s. Pinaki and Company, Chartered Accountants
3	Ayurvedic, Modern Herbal and Neutraceuticals converted into Active Pharmaceuticals (API) (Revised)	Within 2.5 years of receiving IPO fund	Within 2-3 years after getting permission from the Ministry of Industries	Civil Construction Machinery & Equipment Utility Warehouse Vehicle Consultancy fee Contingencies Sub Total	417,500,000 857,200,000 404,000,000 11,000,000 5,000,000 33,900,000 16,900,000 1,745,500,000	417,500,000 857,200,000 404,000,000 11,000,000 5,000,000 33,900,000 16,900,000 1,745,500,000	150,111,346 102,818,652 -	10,054,049 -	160,165,395 102,818,652 -	40.04% 29.56% 0.00%	40.04% 29.56% 0.00%	245,041,348 493,000,000 409,400,000 38,500,000 3,000,000 23,635,200 12,917,600 1,252,409,640	70.44% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 92.41%	
4	Repayment of Bank Borrowing (Revised)	N/A	N/A	Sub Total	1,355,228,292	1,355,228,292	102,818,652	-	102,818,652	7.59%	7.59%	1,252,409,640	92.41%	
5	IPO Expenses	N/A	N/A		N/A	N/A	1,360,000,000	-	1,360,000,000	100.00%	100.00%	-	0.00%	
	Total				4,312,791,870	4,541,520,162	2,232,996,409	168,659,099	2,401,655,508	52.88%	52.88%	2,139,864,654	47.12%	

Percentage (Interest on FDR to be matured on 27 March 2018)

Interest on IPO Proceeds in BDT (from FDR & SND)

Un-Utilized IPO Proceeds with interest income in BDT

On Behalf of Board

Fouzia Haque, FCA
(Fouzia Haque, FCA)

Independent Director & Chairman of the Audit Committee

Afzalur Rahman Sinha
(Afzalur Rahman Sinha)
Chairman

134,309,132
1,827,669,225

Pinaki & Co.
15.01.18

Pinaki & Company
Chartered Accountants